Close Menu

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday proposed to cover the anti-PD-1 drug nivolumab (Bristol Myers Squibb's Opdivo) as a second-line option for patients with certain kinds of non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.